Humana
HUM
$363.86
-0.76%
Humana Inc. is one of the largest private health insurers in the United States, specializing in government-sponsored programs such as Medicare, Medicaid, and the military's Tricare program, while also providing primary-care, at-home, and pharmacy benefit management services. As a dominant player in the Medicare Advantage market, Humana distinguishes itself through its integrated healthcare delivery model, including its CenterWell primary care and pharmacy network. The stock has been a focal point of investor attention following a sharp recovery from a 2025 trough, driven by a favorable 2027 Medicare Advantage payment rate increase from CMS announced in April 2026, which boosted revenue visibility across the managed care sector. Additionally, Humana's strategic moves, including its reported interest in acquiring MaxHealth, have fueled debate about its growth trajectory and margin expansion potential.…
HUM
Humana
$363.86
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. Humana's strong operational turnaround and favorable regulatory catalyst are offset by a premium valuation that already prices in much of the good news. The analyst consensus is Buy with an average target of $347.96, implying -10.6% downside from the current price, suggesting the stock is fully valued near term.
Supporting evidence: Revenue grew 23.47% YoY in Q1 2026, net income swung to $1.186 billion from a loss, free cash flow turned positive at $1.133 billion, and the CMS payment increase provides a multi-year tailwind. However, the trailing P/E of 25.95x is above the 5-year average of ~18x, and the forward P/E of 24.29x exceeds the managed care industry norm of 15-20x. The stock's 1-year return of +69.85% far outpaces the S&P 500's +16.47%, indicating much of the optimism is already priced in.
Risks & Conditions: The biggest risks are valuation compression if earnings growth slows, regulatory changes to Medicare Advantage, and integration risk from the potential MaxHealth acquisition. This Hold would upgrade to Buy if the stock pulls back to the analyst average target of $347.96 or below, or if forward P/E compresses below 20x. It would downgrade to Sell if revenue growth decelerates below 10% or if medical cost ratios spike. Overall, Humana appears fairly valued to slightly overvalued relative to its history and peers.
Sign up to view all
HUM 12-Month Price Forecast
Humana's fundamentals have improved markedly, with strong revenue growth and a return to profitability. However, the stock's valuation has expanded significantly, now trading above the average analyst target. The neutral stance reflects the balance between positive operational momentum and the risk of mean reversion in valuation. Key factors to watch are the sustainability of margin improvement and the outcome of the MaxHealth acquisition. An upgrade to bullish would require evidence of sustained margin expansion and a pullback to more attractive valuation levels, while a downgrade to bearish would follow any deterioration in medical cost trends or regulatory headwinds.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $401.30 and implied upside of +10.3% versus the current price.
Average Target
$401.30
0 analysts
Implied Upside
+10.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$249 - $513
Analyst target range
Humana is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.5 on a 1-5 scale, where 1 is Strong Buy). The average target price is $347.96, which implies a downside of -10.6% from the current price of $389.32. This bearish divergence between the buy rating and the below-market target suggests analysts see value but believe the stock has run ahead of fundamentals. The target range spans from a low of $195.00 to a high of $502.00, indicating significant uncertainty. The high target of $502 assumes continued margin expansion and strong Medicare Advantage growth, while the low target of $195 reflects risks such as regulatory changes or competitive pressures. Recent ratings actions show a mix: Wells Fargo upgraded to Overweight in July 2026, while firms like Truist, TD Cowen, and JP Morgan maintain Hold/Neutral stances. The wide spread between the low and high targets (over $300) underscores high uncertainty, and the fact that the current price exceeds the average target suggests that the market is more optimistic than the analyst consensus, which could lead to volatility if earnings fail to meet elevated expectations.
Drowning in data?
Find the real signal!
Bulls vs Bears: HUM Investment Factors
Humana presents a compelling turnaround story with accelerating revenue, a sharp profitability recovery, and a favorable regulatory catalyst from CMS payment increases. The stock has surged 69.85% over the past year, dramatically outperforming the S&P 500. However, the current price exceeds the average analyst target, and valuation multiples are elevated relative to history and peers. The key tension is whether the strong operational momentum can justify the premium valuation, or if the stock has run ahead of fundamentals. Currently, the bull case has stronger evidence given the tangible revenue and earnings improvements, but the bear case highlights the risk of mean reversion if growth decelerates.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 23.47% YoY to $39.648 billion, driven by strong Medicare Advantage enrollment and premium increases. This acceleration from prior quarters signals robust top-line momentum.
- Profitability Turnaround: Net income swung from a loss of $796 million in Q4 2025 to a profit of $1.186 billion in Q1 2026, with EPS of $9.85. Operating margin improved from -3.15% to 3.98%, indicating effective cost management.
- Favorable CMS Payment Increase: The larger-than-expected 2027 Medicare Advantage payment rate increase from CMS, announced in April 2026, provides multi-year revenue visibility. This catalyst drove a sharp rally from $197 to over $400.
- Strong Free Cash Flow Generation: Q1 2026 free cash flow was $1.133 billion, reversing from negative $1.854 billion in Q4 2025. The FCF yield of ~4.1% supports debt servicing and potential shareholder returns.
Bearish
- Stock Trades Above Analyst Target: At $389.32, the stock is 11.9% above the average analyst target of $347.96. This divergence suggests the market has priced in optimistic expectations that may not materialize.
- Elevated Valuation vs. History: The trailing P/E of 25.95x is well above the 5-year average of ~18x. The forward P/E of 24.29x also exceeds the managed care industry norm of 15-20x, leaving limited room for error.
- Low Current Ratio Indicates Liquidity Risk: The current ratio of 0.72 means short-term liabilities exceed current assets. While common in insurance, this could pressure liquidity if claims spike or investment losses occur.
- Earnings Volatility and Margin Pressure: Net margin in Q1 2026 was 2.99%, below the 3.87% in Q1 2025. The company has experienced quarterly losses in recent periods, highlighting the cyclicality of medical cost ratios.
HUM Technical Analysis
Humana's stock is in a powerful sustained uptrend, with a 1-year price change of +69.85%, dramatically outperforming the S&P 500's +16.47% over the same period. The current price of $389.32 sits at 90.8% of its 52-week range ($163.11 to $428.88), indicating the stock is near the top of its range and reflecting strong bullish momentum. This positioning near highs suggests the market is pricing in continued positive catalysts, though it also raises the risk of overextension in the near term. Short-term momentum is accelerating sharply, with 1-month and 3-month price changes of +7.65% and +80.89%, respectively, compared to the S&P 500's +0.78% and +3.50%. The 3-month surge far outpaces the 1-year trend, signaling a recent inflection point—likely tied to the CMS payment increase—that has driven a powerful breakout. The 1-month gain, while still strong, shows some deceleration from the blistering 3-month pace, suggesting the initial euphoria may be moderating. The stock's beta of 0.717 indicates it is less volatile than the overall market, which is unusual given the recent price swings; this may reflect the stock's prior downtrend and subsequent recovery. Key support lies at the 52-week low of $163.11, while resistance is at the 52-week high of $428.88. A breakout above $428.88 would signal a continuation of the uptrend and likely attract further buying, while a breakdown below recent support near $360 (the June consolidation area) could indicate a pullback. The stock's low beta suggests that any downside may be more measured relative to the market, but the wide 52-week range highlights the potential for significant volatility.
Beta
0.72
0.72x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+45.6%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | -11.1% | +0.2% |
| 3m | +55.7% | +3.7% |
| 6m | +86.4% | +8.0% |
| 1y | +45.6% | +18.2% |
| ytd | +37.6% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Humana's revenue trajectory is robust and accelerating, with Q1 2026 revenue of $39.648 billion, up 23.47% year-over-year from $32.112 billion in Q1 2025. This growth is driven by the Insurance Segment ($38.059 billion) and the CenterWell Segment ($6.1 billion), with the insurance business benefiting from higher Medicare Advantage enrollment and premium rate increases. The multi-quarter trend shows revenue climbing from $29.213 billion in Q4 2024 to $39.648 billion in Q1 2026, reflecting consistent expansion. This accelerating growth supports the investment case, as Humana capitalizes on favorable demographic trends and government program expansions. Profitability has improved markedly, with Q1 2026 net income of $1.186 billion and EPS of $9.85, compared to a net loss of $796 million in Q4 2025. Gross margin expanded to 14.98% in Q1 2026 from 11.67% in Q4 2025, while operating margin rebounded to 3.98% from -3.15%. The net margin of 2.99% in Q1 2026 is still below the 3.87% in Q1 2025, but the trajectory is positive. These margins are typical for the managed care industry, where low margins are offset by high volume. Humana's balance sheet is moderately leveraged, with a debt-to-equity ratio of 0.73 and a current ratio of 0.72, indicating that short-term liabilities exceed current assets. However, the company generated $1.254 billion in operating cash flow and $1.133 billion in free cash flow in Q1 2026, a sharp reversal from negative free cash flow in Q4 2025 (-$1.854 billion). ROE stands at 6.73%, and the free cash flow yield (FCF/market cap) is approximately 4.1%, suggesting adequate cash generation to fund operations and growth without heavy reliance on external financing.
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given Humana's positive net income ($1.186 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 25.95x, while the forward P/E is 24.29x, implying that the market expects earnings growth to continue. The gap between trailing and forward P/E suggests modest growth expectations, which is consistent with the company's improving profitability. Compared to the industry average (not provided, but managed care typically trades at 15-20x forward earnings), Humana's forward P/E of 24.29x appears at a premium. The P/S ratio of 0.24x is low, reflecting the high-revenue, low-margin nature of the business. Historically, Humana's trailing P/E of 25.95x is above its 5-year average of approximately 18x (based on historical data from 2021-2026, where P/E ranged from 4.4x in Q1 2026 to 40.1x in Q3 2025). The current P/E is near the higher end of its historical band, suggesting the market is pricing in optimistic expectations for earnings recovery and growth. This premium may be justified by the recent acceleration in revenue and profitability, but it also leaves limited room for disappointment.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Humana's balance sheet shows a debt-to-equity ratio of 0.73 and a current ratio of 0.72, indicating that short-term liabilities exceed current assets. While the company generated $1.133 billion in free cash flow in Q1 2026, the prior quarter saw negative free cash flow of -$1.854 billion, highlighting cash flow volatility. Net margin of 2.99% in Q1 2026 is below the 3.87% in Q1 2025, and the operating margin of 3.98% remains thin, typical for the industry but vulnerable to medical cost inflation. The reliance on Medicare Advantage means any adverse change in government reimbursement rates could severely impact profitability.
Market & Competitive Risks: The stock's beta of 0.717 suggests lower market correlation, but the recent rally has pushed valuation to a trailing P/E of 25.95x, above the 5-year average of ~18x. This premium pricing leaves the stock susceptible to multiple compression if growth disappoints. Competitors like UnitedHealth and CVS Health also benefit from the CMS payment increase, and Humana's reported interest in acquiring MaxHealth could signal a need to scale up to remain competitive. Regulatory risk is elevated given the political sensitivity of Medicare Advantage payments.
Worst-Case Scenario: A combination of higher-than-expected medical costs, regulatory cuts to Medicare Advantage rates, and integration issues from the MaxHealth acquisition could trigger a sharp re-rating. In such a scenario, the stock could fall to the analyst low target of $195.00, representing a -49.9% decline from the current price of $389.32. The 52-week low of $163.11 would imply a -58.1% loss, though this extreme is less likely given the improved fundamentals.
FAQ
The primary risks are: 1) Valuation risk: The trailing P/E of 25.95x is well above historical averages, leaving the stock vulnerable to multiple compression if growth disappoints. 2) Regulatory risk: Medicare Advantage rates are subject to annual CMS adjustments; any unfavorable change could pressure margins. 3) Operational risk: The current ratio of 0.72 indicates liquidity risk, and net margin of 2.99% is thin, making earnings sensitive to medical cost inflation. 4) Acquisition risk: The potential MaxHealth acquisition could increase leverage and integration complexity. The most severe risk is a regulatory cut to Medicare Advantage rates, which could drive the stock to the analyst low target of $195.00.
The 12-month outlook includes three scenarios: a bull case (25% probability) with a target of $420-$502, driven by sustained margin improvement and successful acquisition integration; a base case (50% probability) with a target of $330-$380, assuming growth moderates and valuation compresses toward the analyst average of $347.96; and a bear case (25% probability) with a target of $195-$250, if medical costs rise or regulatory headwinds emerge. The base case is most likely, implying a potential -10.6% downside from the current price. The key assumption is that revenue growth remains above 15% and margins stabilize near Q1 2026 levels.
Humana's trailing P/E of 25.95x is above its 5-year average of approximately 18x and above the managed care industry norm of 15-20x forward earnings. The forward P/E of 24.29x also suggests a premium. The P/S ratio of 0.24x is low, reflecting the high-revenue, low-margin nature of the business. Compared to peers, the stock appears overvalued relative to historical multiples, but the premium may be justified by the recent acceleration in revenue growth and profitability improvement. The market is pricing in optimistic expectations for continued margin expansion and enrollment gains. Overall, HUM is fairly valued to slightly overvalued, with limited margin of safety.
Humana offers a compelling turnaround story with 23.47% revenue growth and a return to profitability, but the stock trades at a premium valuation with a trailing P/E of 25.95x, above its 5-year average of ~18x. The analyst consensus is Buy, but the average target of $347.96 implies -10.6% downside from the current price of $389.32. For long-term investors with a 3-5 year horizon, the demographic tailwind from aging baby boomers and the CMS payment increase provide a solid foundation. However, near-term buyers face the risk of mean reversion if growth decelerates. It is a good buy on pullbacks toward the analyst target, but less attractive at current levels.
Humana is better suited for long-term investment given its exposure to demographic trends and the multi-year visibility from the CMS payment increase. The beta of 0.717 indicates lower volatility than the market, making it a relatively stable holding. The dividend yield of 1.39% provides modest income. Short-term traders may find opportunities around earnings announcements and regulatory updates, but the stock's recent 69.85% rally suggests near-term upside is limited. A minimum holding period of 3-5 years is recommended to allow the Medicare Advantage growth story to fully play out and to ride out any valuation mean reversion.
